levomepromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1752	60-99-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methotrimeprazine hirnamin levomeprazine levomepromazin levopromazine levoprome levopromethazine levotomin mepromazine levomepromazine levomepromazine maleate methotrimeprazine hydrochloride nozinan	A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) Molecular weight: 328.47 Formula: C19H24N2OS CLOGP: 5.03 LIPINSKI: 1 HAC: 3 HDO: 0 TPSA: 15.71 ALOGS: -4.80 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methotrimeprazine
hirnamin
levomeprazine
levomepromazin
levopromazine
levoprome
levopromethazine
levotomin
mepromazine
levomepromazine
levomepromazine maleate
methotrimeprazine hydrochloride
nozinan

A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)

Molecular weight: 328.47
Formula: C19H24N2OS
CLOGP: 5.03
LIPINSKI: 1
HAC: 3
HDO: 0
TPSA: 15.71
ALOGS: -4.80
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
None	FDA	IMMUNEX

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional overdose	274.65	23.44	141	6619	74011	63408251
Somnolence	177.95	23.44	149	6611	178536	63303726
Intentional self-injury	173.16	23.44	74	6686	25613	63456649
Drug interaction	128.24	23.44	139	6621	228992	63253270
Toxicity to various agents	126.34	23.44	143	6617	247107	63235155
Electrocardiogram QT prolonged	107.19	23.44	71	6689	59459	63422803
Excessive eye blinking	100.28	23.44	24	6736	1256	63481006
Extrapyramidal disorder	98.57	23.44	41	6719	13243	63469019
Urinary retention	82.27	23.44	47	6713	30254	63452008
Neuroleptic malignant syndrome	82.07	23.44	35	6725	12021	63470241
Sopor	81.40	23.44	42	6718	22122	63460140
Drug abuse	77.19	23.44	63	6697	72455	63409807
Altered state of consciousness	73.54	23.44	41	6719	25189	63457073
Suicide attempt	60.80	23.44	51	6709	60867	63421395
Biliary tract infection	49.03	23.44	12	6748	690	63481572
Poisoning deliberate	46.26	23.44	23	6737	11195	63471067
Depressed level of consciousness	46.12	23.44	44	6716	62034	63420228
Cholangitis infective	45.52	23.44	10	6750	356	63481906
Aggression	39.77	23.44	27	6733	23471	63458791
Hallucination, auditory	37.79	23.44	21	6739	12803	63469459
Product use in unapproved indication	37.71	23.44	68	6692	179012	63303250
Mental disorder	37.38	23.44	27	6733	25892	63456370
Bacillus infection	37.11	23.44	10	6750	843	63481419
Hyperprolactinaemia	35.68	23.44	14	6746	3886	63478376
Vascular pain	33.21	23.44	9	6751	775	63481487
Asphyxia	32.57	23.44	15	6745	6166	63476096
Flat affect	31.87	23.44	10	6750	1440	63480822
Psychiatric symptom	31.73	23.44	14	6746	5209	63477053
Hypothermia	31.41	23.44	19	6741	13562	63468700
Tension	31.18	23.44	12	6748	3163	63479099
Illusion	30.44	23.44	9	6751	1061	63481201
Overdose	29.89	23.44	48	6712	115030	63367232
Perforation	29.55	23.44	9	6751	1174	63481088
Diabetic hyperosmolar coma	29.30	23.44	7	6753	363	63481899
Withdrawal syndrome	29.22	23.44	21	6739	19976	63462286
Galactorrhoea	28.06	23.44	12	6748	4143	63478119
Pulmonary embolism	28.05	23.44	47	6713	116637	63365625
Disinhibition	27.65	23.44	8	6752	875	63481387
Behaviour disorder	27.57	23.44	11	6749	3188	63479074
Intestinal obstruction	27.01	23.44	24	6736	30875	63451387
Blood prolactin increased	26.61	23.44	11	6749	3492	63478770
Muscle rigidity	26.36	23.44	16	6744	11484	63470778
Agitation	26.10	23.44	32	6728	59725	63422537
Schizophrenia	25.83	23.44	15	6745	9937	63472325
Psychomotor retardation	25.55	23.44	11	6749	3859	63478403
Bradykinesia	25.50	23.44	12	6748	5176	63477086
Respiratory acidosis	25.43	23.44	13	6747	6702	63475560
Depressed mood	25.23	23.44	26	6734	40165	63442097
Seizure	24.93	23.44	48	6712	132586	63349676
Partial seizures with secondary generalisation	23.54	23.44	6	6754	407	63481855
Antipsychotic drug level increased	23.46	23.44	10	6750	3425	63478837

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	164.41	24.70	77	6791	17857	34932206
Drug abuse	137.20	24.70	130	6738	98966	34851097
Intentional self-injury	110.56	24.70	54	6814	13717	34936346
Extrapyramidal disorder	104.88	24.70	51	6817	12829	34937234
Suicide attempt	97.08	24.70	72	6796	39044	34911019
Toxicity to various agents	79.02	24.70	141	6727	200221	34749842
Dystonic tremor	78.76	24.70	16	6852	203	34949860
Sopor	78.12	24.70	41	6827	12095	34937968
Drug interaction	75.40	24.70	148	6720	225798	34724265
Dystonia	70.83	24.70	37	6831	10808	34939255
Intestinal haemorrhage	69.21	24.70	26	6842	3470	34946593
Blood glucose fluctuation	69.04	24.70	27	6841	4017	34946046
Acute pulmonary oedema	65.60	24.70	31	6837	7312	34942751
Blood creatine phosphokinase increased	60.27	24.70	58	6810	44799	34905264
Intentional overdose	57.79	24.70	56	6812	43618	34906445
Psychomotor hyperactivity	57.67	24.70	31	6837	9591	34940472
Cognitive disorder	56.32	24.70	46	6822	28647	34921416
Blood glucose abnormal	55.86	24.70	26	6842	5926	34944137
Electrocardiogram QT prolonged	55.11	24.70	53	6815	40899	34909164
Altered state of consciousness	52.00	24.70	40	6828	22853	34927210
Restlessness	48.22	24.70	40	6828	25442	34924621
Wrong patient received product	46.29	24.70	18	6850	2636	34947427
Feelings of worthlessness	45.92	24.70	11	6857	308	34949755
Abulia	43.60	24.70	12	6856	588	34949475
Parkinsonism	42.65	24.70	24	6844	8114	34941949
Sudden death	42.25	24.70	30	6838	15171	34934892
Sedation	41.89	24.70	34	6834	20972	34929091
Miosis	41.69	24.70	25	6843	9510	34940553
Somnolence	40.85	24.70	76	6792	111040	34839023
Dyspnoea	38.69	24.70	13	6855	376769	34573294
Rhabdomyolysis	37.64	24.70	56	6812	68107	34881956
Victim of chemical submission	37.49	24.70	7	6861	55	34950008
Gastrointestinal hypermotility	37.08	24.70	8	6860	138	34949925
Electrocardiogram QT shortened	36.66	24.70	8	6860	146	34949917
Urinary incontinence	36.48	24.70	30	6838	18844	34931219
Wrong schedule	35.24	24.70	8	6860	176	34949887
Schizophrenia	33.49	24.70	21	6847	8645	34941418
Drug screen false positive	32.48	24.70	10	6858	729	34949334
Aggression	32.23	24.70	39	6829	38925	34911138
Restless legs syndrome	31.67	24.70	20	6848	8334	34941729
Contraindicated product administered	31.16	24.70	29	6839	21452	34928611
Obsessive-compulsive disorder	30.76	24.70	17	6851	5547	34944516
Hyperhidrosis	30.62	24.70	54	6814	75638	34874425
Confusional state	30.55	24.70	79	6789	144081	34805982
Therapeutic product effect incomplete	30.03	24.70	43	6825	50498	34899565
Balance disorder	29.32	24.70	38	6830	40616	34909447
Mumps	29.19	24.70	6	6862	81	34949982
Salivary hypersecretion	28.60	24.70	19	6849	8625	34941438
Depressed level of consciousness	27.76	24.70	38	6830	42803	34907260
Respiratory depression	27.64	24.70	24	6844	16221	34933842
Coma	27.34	24.70	39	6829	45639	34904424
Overdose	27.05	24.70	57	6811	91002	34859061
Haematoma	26.87	24.70	29	6839	25576	34924487
Product administration error	25.52	24.70	23	6845	16321	34933742
Neurological decompensation	24.89	24.70	12	6856	2954	34947109

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	244.87	20.82	109	12723	27450	79704106
Intentional overdose	216.09	20.82	160	12672	105800	79625756
Intentional self-injury	189.14	20.82	96	12736	32323	79699233
Somnolence	184.40	20.82	209	12623	238772	79492784
Drug abuse	182.61	20.82	174	12658	162517	79569039
Extrapyramidal disorder	164.71	20.82	78	12754	22601	79708955
Drug interaction	156.11	20.82	256	12576	414927	79316629
Sopor	147.96	20.82	82	12750	32928	79698628
Suicide attempt	144.28	20.82	114	12718	82818	79648738
Toxicity to various agents	141.31	20.82	247	12585	421293	79310263
Electrocardiogram QT prolonged	121.41	20.82	107	12725	90279	79641277
Altered state of consciousness	107.19	20.82	74	12758	43748	79687808
Dystonic tremor	81.94	20.82	16	12816	203	79731353
Blood creatine phosphokinase increased	78.41	20.82	73	12759	66017	79665539
Psychomotor hyperactivity	73.13	20.82	41	12791	16808	79714748
Excessive eye blinking	70.43	20.82	21	12811	1680	79729876
Aggression	69.72	20.82	61	12771	50897	79680659
Dystonia	66.55	20.82	42	12790	21357	79710199
Depressed level of consciousness	61.87	20.82	77	12755	96575	79634981
Wrong patient received product	56.71	20.82	23	12809	4595	79726961
Psychiatric symptom	56.64	20.82	26	12806	7009	79724547
Restlessness	52.53	20.82	50	12782	46442	79685114
Acute pulmonary oedema	49.50	20.82	30	12802	14200	79717356
Intestinal haemorrhage	49.40	20.82	23	12809	6403	79725153
Poisoning deliberate	48.87	20.82	33	12799	18795	79712761
Sudden death	48.05	20.82	35	12797	22476	79709080
Overdose	46.63	20.82	96	12736	184110	79547446
Urinary retention	46.01	20.82	51	12781	56579	79674977
Coma	45.86	20.82	68	12764	100581	79630975
Pneumonia aspiration	43.88	20.82	54	12778	66913	79664643
Akathisia	43.69	20.82	27	12805	13232	79718324
Schizophrenia	42.33	20.82	28	12804	15412	79716144
Feelings of worthlessness	42.10	20.82	11	12821	541	79731015
Substance abuse	41.34	20.82	24	12808	10502	79721054
Rhabdomyolysis	40.43	20.82	65	12767	103066	79628490
Muscle rigidity	40.38	20.82	30	12802	19852	79711704
Salivary hypersecretion	39.49	20.82	26	12806	14198	79717358
Cognitive disorder	37.39	20.82	51	12781	69875	79661681
Hypothermia	36.80	20.82	30	12802	22716	79708840
Blood glucose fluctuation	36.65	20.82	19	12813	6663	79724893
Agitation	36.59	20.82	61	12771	99654	79631902
Depressed mood	36.55	20.82	42	12790	48438	79683118
Biliary tract infection	36.04	20.82	12	12820	1376	79730180
Parkinsonism	35.88	20.82	26	12806	16558	79714998
Sedation	35.87	20.82	43	12789	51852	79679704
Abulia	35.42	20.82	11	12821	1009	79730547
Rash	35.39	20.82	25	12807	578333	79153223
Ileus paralytic	35.32	20.82	21	12811	9599	79721957
Cholangitis infective	35.31	20.82	10	12822	667	79730889
Blood glucose abnormal	33.50	20.82	21	12811	10545	79721011
Obsessive-compulsive disorder	32.93	20.82	17	12815	5910	79725646
Pain	31.83	20.82	40	12792	703762	79027794
Wrong schedule	31.29	20.82	8	12824	361	79731195
Arthralgia	30.86	20.82	28	12804	571775	79159781
Drug screen false positive	30.44	20.82	10	12822	1099	79730457
Intestinal obstruction	30.31	20.82	36	12796	42984	79688572
Bacillus infection	30.04	20.82	10	12822	1145	79730411
Mania	29.36	20.82	24	12808	18236	79713320
Mental disorder	28.59	20.82	30	12802	31272	79700284
Joint swelling	28.23	20.82	6	12826	288640	79442916
Hallucination	28.23	20.82	50	12782	85695	79645861
Vascular pain	28.17	20.82	9	12823	906	79730650
Miosis	28.05	20.82	22	12810	15767	79715789
Hyperprolactinaemia	27.69	20.82	14	12818	4662	79726894
Asthenia	27.67	20.82	25	12807	511664	79219892
Colitis ischaemic	26.42	20.82	21	12811	15338	79716218
Behaviour disorder	26.41	20.82	15	12817	6298	79725258
Hyperhidrosis	26.21	20.82	68	12764	151424	79580132
Product use in unapproved indication	26.04	20.82	94	12738	250265	79481291
Tachycardia	25.98	20.82	75	12757	177693	79553863
Tremor	25.09	20.82	72	12760	170011	79561545
Cough	24.96	20.82	14	12818	366775	79364781
Abnormal behaviour	24.87	20.82	30	12802	36391	79695165
Deep vein thrombosis	24.86	20.82	58	12774	120861	79610695
Galactorrhoea	24.81	20.82	12	12820	3634	79727922
Asphyxia	24.50	20.82	18	12814	11702	79719854
Perforation	24.26	20.82	9	12823	1417	79730139
Neuroleptic-induced deficit syndrome	23.31	20.82	4	12828	23	79731533
Seizure	23.23	20.82	75	12757	188759	79542797
Confusional state	23.22	20.82	107	12725	317890	79413666
Therapeutic product effect incomplete	22.90	20.82	62	12770	141583	79589973
Tension	22.67	20.82	12	12820	4392	79727164
Eosinophilia	22.63	20.82	32	12800	45313	79686243
Illusion	22.51	20.82	9	12823	1732	79729824
Megacolon	22.28	20.82	11	12821	3484	79728072
Restless legs syndrome	21.54	20.82	21	12811	20071	79711485
Withdrawal syndrome	21.49	20.82	24	12808	26830	79704726
Psychomotor retardation	21.41	20.82	13	12819	6171	79725385
Disturbance in attention	21.25	20.82	33	12799	50768	79680788
Diabetic hyperosmolar coma	21.13	20.82	7	12825	790	79730766
Flat affect	21.13	20.82	9	12823	2032	79729524
Hallucination, auditory	21.02	20.82	21	12811	20672	79710884
Blood prolactin increased	20.84	20.82	11	12821	4000	79727556

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AA02	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with aliphatic side-chain
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018689	Sensory System Agents
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drugs
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:149553	anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	4.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	9.24		PDSP
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.02		CHEMBL

External reference:

ID	Source
4018915	VUID
N0000147208	NUI
D00403	KEGG_DRUG
4018915	VANDF
CHEBI:6838	CHEBI
CHEMBL1764	ChEMBL_ID
CHEMBL1725730	ChEMBL_ID
C017901	MESH_SUPPLEMENTAL_RECORD_UI
7603	IUPHAR_LIGAND_ID
705	INN_ID
7104-38-3	SECONDARY_CAS_RN
DB01403	DRUGBANK_ID
9G0LAW7ATQ	UNII
160372	RXNORM
1834	MMSL
5078	MMSL
d00814	MMSL
001581	NDDF
004134	NDDF
005070	NDDF
387509007	SNOMEDCT_US
395790003	SNOMEDCT_US
57911003	SNOMEDCT_US
89029005	SNOMEDCT_US
C0025678	UMLSCUI
D008728	MESH_DESCRIPTOR_UI
CHEMBL2104973	ChEMBL_ID
72287	PUBCHEM_CID

Pharmaceutical products:

None